The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial

Grimnes, Guri; Joakimsen, Ragnar Martin; Figenschau, Yngve; Torjesen, Peter A.; Almås, Bjørg; Jorde, Rolf

doi:10.1007/s00198-011-1752-5

Cited by 66 publications

(82 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As expected, there was a clear difference between the genotype risk quartiles regarding serum 25(OH)D but not regarding age or BMI ( Table 1). As previously published, the intake of vitamin D in the three studies was safe with no serious side effects, and in all three studies, there was a significant decrease in serum PTH after vitamin D supplementation (18,19,20).…”

Section: Resultssupporting

confidence: 72%

“…In addition, all subjects were given daily supplements with 1 g calcium and 800 IU vitamin D (ClinicalTrials.gov NTC00491920) (18 (20).…”

Section: Study Populationmentioning

confidence: 99%

“…BMI was calculated as weight divided by height squared. Serum PTH was measured as described previously (18). Serum 25(OH)D was measured with an LC-MSMS method (19).…”

Section: Measurementsmentioning

confidence: 99%

See 2 more Smart Citations

The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels

Didriksen

Grimnes

Hutchinson

et al. 2013

European Journal of Endocrinology

101

View full text Add to dashboard Cite

Objective: The serum 25-hydroxyvitamin D (25(OH)D) level is not only dependent on vitamin D intake and production in the skin but also dependent on genetic factors. Thus, in large genome-wide association studies, it has been shown that single nucleotide polymorphisms (SNPs) in the vitamin D binding protein (DBP), as well as in enzymes related to activation or degradation of vitamin D and its metabolites, are as important for the serum 25(OH)D level as the effect of season. How these SNPs affect the serum 25(OH)D response to vitamin D supplementation is uncertain. Design and methods: Data were pooled from three randomized controlled trials where 40 000 IU vitamin D/week was given for 6 months. Serum 25(OH)D was measured before and at the end of the intervention, and the subjects were genotyped for SNPs related to the serum 25(OH)D level. Results: Baseline 25(OH)D levels were significantly related to SNPs in the DBP and CYP2R1 genes. Those with SNPs associated with the lowest baseline 25(OH)D levels also had the smallest increase (delta) after supplementation. Those with the lowest baseline serum 25(OH)D (without regard to genotypes) had the highest increase (delta) after supplementation. Subjects with high BMI had lowest baseline 25(OH)D levels and also the smallest increase (delta) after supplementation. Conclusions: The serum 25(OH)D response to supplementation depends on genes, baseline level, and BMI. However, whether this is clinically important or not depends on the therapeutic window of vitamin D, an issue that is still not settled.

show abstract

Section: Resultssupporting

confidence: 72%

“…In addition, all subjects were given daily supplements with 1 g calcium and 800 IU vitamin D (ClinicalTrials.gov NTC00491920) (18 (20).…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels

Didriksen

Grimnes

Hutchinson

et al. 2013

European Journal of Endocrinology

101

View full text Add to dashboard Cite

show abstract

“…En adultos sanos la suplementación con Vitamina D no previene Osteoporosis, pero en los ancianos mantener adecuadas reservas de vitamina D combinado con ingesta sufi ciente de calcio es una efectiva estrategia para prevenir fracturas de cadera. (290)(291)(292)(293)(294)(295)(296)(297)(298)(299)(300).…”

Section: Calcio Y Riesgo Cardiovascularunclassified

Calcio como agente terapéutico en osteoporosis

Roa¹,

Guzmán

Rodríguez

et al. 2017

rev cuarzo

View full text Add to dashboard Cite

Osteoporosis is a metabolic disease that produces a quantitatively defi cient, poor-quality, fracture-prone bone that is treated with calcium. Although the benefi cial effects of this element are known, recent reports associate it with cardiovascular complications. Taking into account the above, this review sought to capture the state of the Licencia creative commonsCalcio como agente terapéutico en osteoporosis Roa G. y cols.

show abstract

“…In the present study, we pooled baseline data from a vitamin D and bone-density study including 297 postmenopausal women aged 50-80 years with a T-score in total hip or lumbar spine (L2-4) £ -2.0 (22), and a vitamin D and depression study comprising 357 subjects aged 30-75 years (23). Serum TSH, fT4, and fT3 were measured as previously described (9).…”

Section: Definition Of Endpointsmentioning

confidence: 99%

The Phosphodiesterase 8B Gene rs4704397 is Associated with Thyroid Function, Risk of Myocardial Infarction, and Body Height: The Tromsø Study

Jorde

Schirmer

Wilsgaard

et al. 2014

Thyroid

View full text Add to dashboard Cite

Objective: High serum thyrotropin (TSH) levels predict cardiovascular disease (CVD). Recently several single nucleotide polymorphisms (SNPs) associated with TSH levels have been identified, one of them being the rs4704397 SNP in the phosphodiesterase 8B (PDE8B) gene. If the relation between thyroid function and CVD is causal, one could also expect rs4704397 genotypes to predict CVD and possibly health in general. Methods: DNA was prepared and genotyping performed for rs4704397 in subjects who participated in the fourth survey of the Tromsø Study in 1994-1995 and who were registered with the endpoints myocardial infarction (MI), type 2 diabetes (T2DM), cancer, or death, as well as a randomly selected control group. Similarly, genotyping was performed in subjects who had participated in clinical trials where serum TSH, free T4 (fT4), and free T3 (fT3) were measured. Results: From the Tromsø Study, 8938 subjects without thyroid disease or thyroid medication were successfully genotyped for rs4704397. Among these, 2098 were registered with MI, 1025 with T2DM, 2748 with cancer, and 3592 had died. The minor homozygote genotype (A:A) had a median serum TSH level that was 0.29 mIU/L higher than in the major homozygote genotype (G:G). The A:A genotype had a significantly increased risk of MI as compared to the G:G genotype (1.14 [1.00-1.29], hazard ratio [confidence interval], Cox regression with adjustment for age, sex, and body mass index). No significant associations were seen with the other endpoints or CVD risk factors. Furthermore, subjects with the G:G genotype were significantly taller than subjects with the A:A genotype (mean difference 1.5 cm). In 584 subjects with serum TSH, fT4, and fT3 measurements, the subjects with the A:A genotype had significantly higher serum TSH and nonsignificantly lower serum fT3 (mean difference 0.15 pmol/L) levels than subjects with the G:G genotype. Conclusion: rs4704397 is associated with thyroid function, risk of MI, and body height. However, confirmation in other cohorts is needed before firm conclusions can be drawn.

show abstract

The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass—a randomized controlled 1-year trial

Abstract: One year treatment with 6,500 IU vitamin D(3)/day was not better than 800 IU/day regarding BMD in vitamin D-replete postmenopausal women with reduced bone mass and was less efficient in reducing bone turnover.

Cited by 66 publications

References 33 publications

The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels

The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels

Calcio como agente terapéutico en osteoporosis

The Phosphodiesterase 8B Gene rs4704397 is Associated with Thyroid Function, Risk of Myocardial Infarction, and Body Height: The Tromsø Study

Contact Info

Product

Resources

About